These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 27419812)

  • 41. Feasibility and acceptability of HIV self-testing among pre-exposure prophylaxis users in Kenya.
    Ngure K; Heffron R; Mugo N; Thomson KA; Irungu E; Njuguna N; Mwaniki L; Celum C; Baeten JM
    J Int AIDS Soc; 2017 Feb; 20(1):21234. PubMed ID: 28362073
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors of interest in taking pre-exposure prophylaxis among men who have sex with men who used a rapid HIV-testing site in Montreal (Actuel sur Rue).
    Lebouché B; Engler K; Machouf N; Lessard D; Thomas R
    HIV Med; 2016 Feb; 17(2):152-8. PubMed ID: 26177691
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs.
    Martin M; Vanichseni S; Suntharasamai P; Sangkum U; Mock PA; Leethochawalit M; Chiamwongpaet S; Curlin ME; Na-Pompet S; Warapronmongkholkul A; Kittimunkong S; Gvetadze RJ; McNicholl JM; Paxton LA; Choopanya K;
    AIDS; 2015 Apr; 29(7):819-24. PubMed ID: 25985403
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low uptake of HIV testing and no HIV positivity in stable serodiscordant heterosexual partners of long-term treated HIV-infected Thais.
    Kancheva Landolt N; Phanuphak N; Khongpetch C; Kriengsinyot R; Teeratakulpisarn S; Ubolyam S; Kerr S; Pinyakorn S; Chaithongwongwatthana S; Phanuphak P; Avihingsanon A; Ananworanich J
    AIDS Care; 2015; 27(5):587-94. PubMed ID: 25506672
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel "HIV salience and Perception" scale is associated with PrEP dispensing and adherence among adolescent girls and young women in Kampala, Uganda.
    Velloza J; Mujugira A; Muwonge T; Boyer J; Nampewo O; Badaru J; Ssebuliba T; Stalter RM; Stein G; Baeten JM; Celum C; Heffron R
    AIDS Behav; 2023 Jan; 27(1):279-289. PubMed ID: 35776250
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Medication adherence among men who have sex with men at risk for HIV infection in the United States: implications for pre-exposure prophylaxis implementation.
    Liu AY; Hessol NA; Vittinghoff E; Amico KR; Kroboth E; Fuchs J; Irvin R; Sineath RC; Sanchez T; Sullivan PS; Buchbinder SP
    AIDS Patient Care STDS; 2014 Dec; 28(12):622-7. PubMed ID: 25396706
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.
    Özdener AE; Park TE; Kalabalik J; Gupta R
    Expert Rev Anti Infect Ther; 2017 May; 15(5):467-481. PubMed ID: 28322067
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial.
    van der Straten A; Mayo A; Brown ER; Amico KR; Cheng H; Laborde N; Marrazzo J; Torjesen K
    AIDS Behav; 2015 May; 19(5):770-83. PubMed ID: 25384907
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIV-Negative Partnered Men's Willingness to Use Pre-Exposure Prophylaxis and Associated Factors Among an Internet Sample of U.S. HIV-Negative and HIV-Discordant Male Couples.
    Mitchell JW; Stephenson R
    LGBT Health; 2015 Mar; 2(1):35-40. PubMed ID: 26790016
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patient perception of community pharmacists prescribing pre-exposure prophylaxis for HIV prevention.
    Zhu V; Tran D; Banjo O; Onuegbu R; Seung H; Layson-Wolf C
    J Am Pharm Assoc (2003); 2020; 60(6):781-788.e2. PubMed ID: 32305210
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM-PrEP participants who seroconverted in Bondo, Kenya, and Pretoria, South Africa.
    Corneli AL; McKenna K; Headley J; Ahmed K; Odhiambo J; Skhosana J; Wang M; Agot K;
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19152. PubMed ID: 25224613
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of Demographic and Socio-Behavioral Factors on Adherence to HIV Pre-Exposure Prophylaxis Using a Markov Modeling Approach.
    Mallayasamy S; Chaturvedula A; Fossler MJ; Sale ME; Hendrix CW; Haberer JE
    Front Pharmacol; 2019; 10():785. PubMed ID: 31354496
    [No Abstract]   [Full Text] [Related]  

  • 53. Trajectories of Oral PrEP Adherence Among Young Kenyan Women: Implications for Promoting Effective PrEP Use.
    Musinguzi N; Pyra M; Bukusi EA; Mugo NR; Baeten JM; Haberer JE;
    AIDS Behav; 2023 Jan; 27(1):171-181. PubMed ID: 35841463
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fertility intentions and interest in early antiretroviral therapy among East African HIV-1-infected individuals in serodiscordant partnerships.
    Mujugira A; Heffron R; Celum C; Mugo N; Nakku-Joloba E; Baeten JM;
    J Acquir Immune Defic Syndr; 2013 May; 63(1):e33-5. PubMed ID: 23574927
    [No Abstract]   [Full Text] [Related]  

  • 55. Engaging young women in Africa for PrEP use and adherence.
    Maharaj B; Karim QA
    Lancet HIV; 2021 Mar; 8(3):e122-e123. PubMed ID: 33662262
    [No Abstract]   [Full Text] [Related]  

  • 56. PrEP introduction for adolescent girls and young women.
    Mathur S; Pilgrim N; Pulerwitz J
    Lancet HIV; 2016 Sep; 3(9):e406-e408. PubMed ID: 27562739
    [No Abstract]   [Full Text] [Related]  

  • 57. Lessons on PrEP from the SEARCH study in east Africa.
    Celum C; Baeten JM
    Lancet HIV; 2020 Apr; 7(4):e219-e220. PubMed ID: 32087151
    [No Abstract]   [Full Text] [Related]  

  • 58. Machine Learning for Human Immunodeficiency Virus Prevention in Rural Africa: The SEARCH for Sustainability.
    Krakower DS; Marcus JL
    Clin Infect Dis; 2020 Dec; 71(9):2334-2335. PubMed ID: 31697379
    [No Abstract]   [Full Text] [Related]  

  • 59. Re: Pre-Exposure Prophylaxis for Mitigating Risk of HIV Transmission During HIV Cure-Related Clinical Trials With a Treatment Interruption.
    Folayan MO; Haire B; Noseda V
    J Infect Dis; 2019 Aug; 220(7):1231-1233. PubMed ID: 31505662
    [No Abstract]   [Full Text] [Related]  

  • 60. Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda.
    Baeten JM; Heffron R; Kidoguchi L; Mugo NR; Katabira E; Bukusi EA; Asiimwe S; Haberer JE; Morton J; Ngure K; Bulya N; Odoyo J; Tindimwebwa E; Hendrix C; Marzinke MA; Ware NC; Wyatt MA; Morrison S; Haugen H; Mujugira A; Donnell D; Celum C;
    PLoS Med; 2016 Aug; 13(8):e1002099. PubMed ID: 27552090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.